Adjuvant chemotherapy in patients with completely resected small cell lung cancer: A retrospective analysis of 26 consecutive cases

Hidenori Mizugaki, Yutaka Fujiwara, Noboru Yamamoto, Shigehiro Yagishita, Satoru Kitazono, Ayako Tanaka, Hidehito Horinouchi, Shintaro Kanda, Hiroshi Nokihara, Koji Tsuta, Hisao Asamura, Tomohide Tamura

Research output: Contribution to journalArticle

Abstract

Objective: Several clinical studies have demonstrated the efficacy and safety of adjuvant chemotherapy in patients with completely resected small cell lung cancer for a selected limited stage. However, it is unclear whether adjuvant chemotherapy is feasible in clinical practice. The objective of this study was to analyze the efficacy and safety of adjuvant chemotherapy for small cell lung cancer patients retrospectively in clinical practice. Methods: From January 2002 to March 2012, 56 small cell lung cancer patients underwent surgery as initial therapy in our institute. Of these, 26 patients received adjuvant chemotherapy. The clinical data of patients who received adjuvant chemotherapy were retrospectively analyzed. Results: The chemotherapy regimens were cisplatin and irinotecan in 16 patients, cisplatin and etoposide in 1 and carboplatin and etoposide in 9. Median follow-up time was 44.8 months. Nineteen (73%) patients received the full course of chemotherapy. Median recurrence-free survival was 21.4 months. Median survival time was not reached. There was no treatment-related death. Conclusion: Adjuvant chemotherapy may be generally safe and efficacious in selected small cell lung cancer patients.

Original languageEnglish
Pages (from-to)835-840
Number of pages6
JournalJapanese Journal of Clinical Oncology
Volume44
Issue number9
DOIs
Publication statusPublished - 2014
Externally publishedYes

Fingerprint

Small Cell Lung Carcinoma
Adjuvant Chemotherapy
irinotecan
Etoposide
Cisplatin
Safety
Drug Therapy
Survival
Carboplatin
Recurrence
Therapeutics

Keywords

  • Adjuvant chemotherapy
  • small cell lung cancer
  • Surgery

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Radiology Nuclear Medicine and imaging
  • Medicine(all)

Cite this

Adjuvant chemotherapy in patients with completely resected small cell lung cancer : A retrospective analysis of 26 consecutive cases. / Mizugaki, Hidenori; Fujiwara, Yutaka; Yamamoto, Noboru; Yagishita, Shigehiro; Kitazono, Satoru; Tanaka, Ayako; Horinouchi, Hidehito; Kanda, Shintaro; Nokihara, Hiroshi; Tsuta, Koji; Asamura, Hisao; Tamura, Tomohide.

In: Japanese Journal of Clinical Oncology, Vol. 44, No. 9, 2014, p. 835-840.

Research output: Contribution to journalArticle

Mizugaki, H, Fujiwara, Y, Yamamoto, N, Yagishita, S, Kitazono, S, Tanaka, A, Horinouchi, H, Kanda, S, Nokihara, H, Tsuta, K, Asamura, H & Tamura, T 2014, 'Adjuvant chemotherapy in patients with completely resected small cell lung cancer: A retrospective analysis of 26 consecutive cases', Japanese Journal of Clinical Oncology, vol. 44, no. 9, pp. 835-840. https://doi.org/10.1093/jjco/hyu092
Mizugaki, Hidenori ; Fujiwara, Yutaka ; Yamamoto, Noboru ; Yagishita, Shigehiro ; Kitazono, Satoru ; Tanaka, Ayako ; Horinouchi, Hidehito ; Kanda, Shintaro ; Nokihara, Hiroshi ; Tsuta, Koji ; Asamura, Hisao ; Tamura, Tomohide. / Adjuvant chemotherapy in patients with completely resected small cell lung cancer : A retrospective analysis of 26 consecutive cases. In: Japanese Journal of Clinical Oncology. 2014 ; Vol. 44, No. 9. pp. 835-840.
@article{692577a531f54b68a54c7c136114d19e,
title = "Adjuvant chemotherapy in patients with completely resected small cell lung cancer: A retrospective analysis of 26 consecutive cases",
abstract = "Objective: Several clinical studies have demonstrated the efficacy and safety of adjuvant chemotherapy in patients with completely resected small cell lung cancer for a selected limited stage. However, it is unclear whether adjuvant chemotherapy is feasible in clinical practice. The objective of this study was to analyze the efficacy and safety of adjuvant chemotherapy for small cell lung cancer patients retrospectively in clinical practice. Methods: From January 2002 to March 2012, 56 small cell lung cancer patients underwent surgery as initial therapy in our institute. Of these, 26 patients received adjuvant chemotherapy. The clinical data of patients who received adjuvant chemotherapy were retrospectively analyzed. Results: The chemotherapy regimens were cisplatin and irinotecan in 16 patients, cisplatin and etoposide in 1 and carboplatin and etoposide in 9. Median follow-up time was 44.8 months. Nineteen (73{\%}) patients received the full course of chemotherapy. Median recurrence-free survival was 21.4 months. Median survival time was not reached. There was no treatment-related death. Conclusion: Adjuvant chemotherapy may be generally safe and efficacious in selected small cell lung cancer patients.",
keywords = "Adjuvant chemotherapy, small cell lung cancer, Surgery",
author = "Hidenori Mizugaki and Yutaka Fujiwara and Noboru Yamamoto and Shigehiro Yagishita and Satoru Kitazono and Ayako Tanaka and Hidehito Horinouchi and Shintaro Kanda and Hiroshi Nokihara and Koji Tsuta and Hisao Asamura and Tomohide Tamura",
year = "2014",
doi = "10.1093/jjco/hyu092",
language = "English",
volume = "44",
pages = "835--840",
journal = "Japanese Journal of Clinical Oncology",
issn = "0368-2811",
publisher = "Oxford University Press",
number = "9",

}

TY - JOUR

T1 - Adjuvant chemotherapy in patients with completely resected small cell lung cancer

T2 - A retrospective analysis of 26 consecutive cases

AU - Mizugaki, Hidenori

AU - Fujiwara, Yutaka

AU - Yamamoto, Noboru

AU - Yagishita, Shigehiro

AU - Kitazono, Satoru

AU - Tanaka, Ayako

AU - Horinouchi, Hidehito

AU - Kanda, Shintaro

AU - Nokihara, Hiroshi

AU - Tsuta, Koji

AU - Asamura, Hisao

AU - Tamura, Tomohide

PY - 2014

Y1 - 2014

N2 - Objective: Several clinical studies have demonstrated the efficacy and safety of adjuvant chemotherapy in patients with completely resected small cell lung cancer for a selected limited stage. However, it is unclear whether adjuvant chemotherapy is feasible in clinical practice. The objective of this study was to analyze the efficacy and safety of adjuvant chemotherapy for small cell lung cancer patients retrospectively in clinical practice. Methods: From January 2002 to March 2012, 56 small cell lung cancer patients underwent surgery as initial therapy in our institute. Of these, 26 patients received adjuvant chemotherapy. The clinical data of patients who received adjuvant chemotherapy were retrospectively analyzed. Results: The chemotherapy regimens were cisplatin and irinotecan in 16 patients, cisplatin and etoposide in 1 and carboplatin and etoposide in 9. Median follow-up time was 44.8 months. Nineteen (73%) patients received the full course of chemotherapy. Median recurrence-free survival was 21.4 months. Median survival time was not reached. There was no treatment-related death. Conclusion: Adjuvant chemotherapy may be generally safe and efficacious in selected small cell lung cancer patients.

AB - Objective: Several clinical studies have demonstrated the efficacy and safety of adjuvant chemotherapy in patients with completely resected small cell lung cancer for a selected limited stage. However, it is unclear whether adjuvant chemotherapy is feasible in clinical practice. The objective of this study was to analyze the efficacy and safety of adjuvant chemotherapy for small cell lung cancer patients retrospectively in clinical practice. Methods: From January 2002 to March 2012, 56 small cell lung cancer patients underwent surgery as initial therapy in our institute. Of these, 26 patients received adjuvant chemotherapy. The clinical data of patients who received adjuvant chemotherapy were retrospectively analyzed. Results: The chemotherapy regimens were cisplatin and irinotecan in 16 patients, cisplatin and etoposide in 1 and carboplatin and etoposide in 9. Median follow-up time was 44.8 months. Nineteen (73%) patients received the full course of chemotherapy. Median recurrence-free survival was 21.4 months. Median survival time was not reached. There was no treatment-related death. Conclusion: Adjuvant chemotherapy may be generally safe and efficacious in selected small cell lung cancer patients.

KW - Adjuvant chemotherapy

KW - small cell lung cancer

KW - Surgery

UR - http://www.scopus.com/inward/record.url?scp=84906850214&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84906850214&partnerID=8YFLogxK

U2 - 10.1093/jjco/hyu092

DO - 10.1093/jjco/hyu092

M3 - Article

C2 - 25097183

AN - SCOPUS:84906850214

VL - 44

SP - 835

EP - 840

JO - Japanese Journal of Clinical Oncology

JF - Japanese Journal of Clinical Oncology

SN - 0368-2811

IS - 9

ER -